INTRODUCTION: The anti-tumor activity of angiogenesis inhibitors is often limited by the development of resistance to these drugs. Here we establish HIF-1α as a major factor in the development of this resistance in neuroblastoma xenografts. METHODS: Neuroblastoma xenografts were established by injecting unmodified SKNAS or NB-1691 cells (2 × 10(6) cells), or cells in which HIF-1α expression had been knocked down with shRNA, into the retroperitoneal space of SCID mice. Treatment of established tumors included bevacizumab (5mg/kg q2wk), sunitinib (40 mg/kg qd), or topotecan (0.5mg/kg qd) alone or in combination for a total of two weeks. RESULTS: NB-1691 xenografts showed no difference in relative growth in HIF-1α knockdowns compared to control tumors (73.33 ± 7.90 vs 79.94 ± 6.15, p=0.528). However, HIF-1α knockdowns demonstrated relative final volumes that were significantly lower than unmodified tumors when both were treated with bevacizumab (35.88 ± 4.24 vs 53.57 ± 6.61, p=0.0544) or sunitinib (12.46 ± 2.59 vs 36.36 ± 4.82, p=0.0024). Monotherapy of unmodified xenografts with bevacizumab, sunitinib, or topotecan was largely ineffective. Relative final volumes of NB-1691 xenografts were significantly less in cohorts treated with sunitinib+topotecan (4.78 ± 0.77 vs 39.17 ± 2.44 [sunitinib alone], p=0.011) and bevacizumab+topotecan (13.63 ± 1.55 vs 48.16 ± 9.94 [bevacizumab alone], p=0.014). CONCLUSION: Upregulation of HIF-1α appears to be a significant mechanism of resistance to antiangiogenic therapies in neuroblastoma. Suppressing HIF-1α with low-dose topotecan potentiates the effects of the antiangiogenic drugs in a mouse model.
INTRODUCTION: The anti-tumor activity of angiogenesis inhibitors is often limited by the development of resistance to these drugs. Here we establish HIF-1α as a major factor in the development of this resistance in neuroblastoma xenografts. METHODS:Neuroblastoma xenografts were established by injecting unmodified SKNAS or NB-1691 cells (2 × 10(6) cells), or cells in which HIF-1α expression had been knocked down with shRNA, into the retroperitoneal space of SCIDmice. Treatment of established tumors included bevacizumab (5mg/kg q2wk), sunitinib (40 mg/kg qd), or topotecan (0.5mg/kg qd) alone or in combination for a total of two weeks. RESULTS: NB-1691 xenografts showed no difference in relative growth in HIF-1α knockdowns compared to control tumors (73.33 ± 7.90 vs 79.94 ± 6.15, p=0.528). However, HIF-1α knockdowns demonstrated relative final volumes that were significantly lower than unmodified tumors when both were treated with bevacizumab (35.88 ± 4.24 vs 53.57 ± 6.61, p=0.0544) or sunitinib (12.46 ± 2.59 vs 36.36 ± 4.82, p=0.0024). Monotherapy of unmodified xenografts with bevacizumab, sunitinib, or topotecan was largely ineffective. Relative final volumes of NB-1691 xenografts were significantly less in cohorts treated with sunitinib+topotecan (4.78 ± 0.77 vs 39.17 ± 2.44 [sunitinib alone], p=0.011) and bevacizumab+topotecan (13.63 ± 1.55 vs 48.16 ± 9.94 [bevacizumab alone], p=0.014). CONCLUSION: Upregulation of HIF-1α appears to be a significant mechanism of resistance to antiangiogenic therapies in neuroblastoma. Suppressing HIF-1α with low-dose topotecan potentiates the effects of the antiangiogenic drugs in a mouse model.
Authors: M B Nilsson; P E Zage; L Zeng; L Xu; T Cascone; H K Wu; B Saigal; P A Zweidler-McKay; J V Heymach Journal: Oncogene Date: 2010-03-08 Impact factor: 9.867
Authors: R Ladenstein; T Philip; C Lasset; O Hartmann; A Garaventa; R Pinkerton; J Michon; J Pritchard; T Klingebiel; B Kremens; A Pearson; C Coze; P Paolucci; D Frappaz; H Gadner; F Chauvin Journal: J Clin Oncol Date: 1998-03 Impact factor: 44.544
Authors: Eugene S Kim; Samuel Z Soffer; Jianzhong Huang; Kimberly W McCrudden; Akiko Yokoi; Christina A Manley; William Middlesworth; Jessica J Kandel; Darrell J Yamashiro Journal: J Pediatr Surg Date: 2002-03 Impact factor: 2.545
Authors: Julia L Glade Bender; Peter C Adamson; Joel M Reid; Lu Xu; Sylvain Baruchel; Yuval Shaked; Robert S Kerbel; Erin M Cooney-Qualter; Diana Stempak; Helen X Chen; Marvin D Nelson; Mark D Krailo; Ashish M Ingle; Susan M Blaney; Jessica J Kandel; Darrell J Yamashiro Journal: J Clin Oncol Date: 2008-01-20 Impact factor: 44.544
Authors: John M Maris; Joshua Courtright; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Lock; Mayamin Tajbakhsh; C Patrick Reynolds; Stephen T Keir; Jianrong Wu; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2008-07 Impact factor: 3.167
Authors: Alvaro Marín-Hernández; Juan C Gallardo-Pérez; Stephen J Ralph; Sara Rodríguez-Enríquez; Rafael Moreno-Sánchez Journal: Mini Rev Med Chem Date: 2009-08 Impact factor: 3.862
Authors: Annamaria Rapisarda; Melinda Hollingshead; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Bradley Gehrs; Mark Raffeld; Robert J Kinders; Ralph Parchment; Miriam R Anver; Robert H Shoemaker; Giovanni Melillo Journal: Mol Cancer Ther Date: 2009-07-07 Impact factor: 6.261
Authors: Paxton V Dickson; John B Hamner; Thomas L Sims; Charles H Fraga; Catherine Y C Ng; Surender Rajasekeran; Nikolaus L Hagedorn; M Beth McCarville; Clinton F Stewart; Andrew M Davidoff Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531
Authors: Andrea L Casillas; Rachel K Toth; Alva G Sainz; Neha Singh; Ankit A Desai; Andrew S Kraft; Noel A Warfel Journal: Clin Cancer Res Date: 2017-10-30 Impact factor: 12.531
Authors: Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang Journal: Med Res Rev Date: 2020-11-06 Impact factor: 12.944